Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 14Neoplasms 11Multiple Myeloma 10Recurrence 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Neuroblastoma 6Melanoma 6Sarcoma 5Leukemia, Myeloid, Acute 5Hematologic Neoplasms 4Glioblastoma 4Colorectal Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neuroectodermal Tumors, Primitive 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Squamous Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2

Interventions

erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Advanced Cancers and FGFR Genetic Alterations × 1 year × Clear all
NCT03825484 2025-06-13

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Janssen Scientific Affairs, LLC

Approved for marketing

Advanced Cancers and FGFR Genetic Alterations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡